Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
Medical and scientific days of The Institute of Oncology Bucharest 2021 : Steps ...
Dr Laurentiu Simion - University of Medicine and Pharmacy, C Davilla Bucharest, ...
Medical and scientific days of The Institute of Oncology Bucharest 2021 : Steps to the Oncology of Tomorrow ( Dr Laurentiu Simion - University of Medicine and Pharmacy, C Davilla Bucharest, Surgeon Institute of Oncology Bucharest )
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021
Breast cancer roundup from ASCO 2021
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2021
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leuka...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC
Dr Christina Baik - University of Washington School of Medicine, Seattle, USA
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )
11 Jun 2021